Literature DB >> 4185592

Azathioprine for Crohn's disease.

B N Brooke, D C Hoffmann, E T Swarbrick.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4185592     DOI: 10.1016/s0140-6736(69)90325-0

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  38 in total

1.  Carcinoembryonic antigen in patients suffering from ulcerative proctocolitis.

Authors:  A B Mitchell; A M Gill; R T Orchard; R A Parkins
Journal:  Am J Dig Dis       Date:  1975-05

Review 2.  Ulcerative colitis and Crohn's colitis: differential diagnosis and treatment.

Authors:  T C Northfield
Journal:  Drugs       Date:  1977-09       Impact factor: 9.546

3.  The effect of azathioprine on cell-mediated immunity (CMI) to Candida albicans in Crohn's disease.

Authors:  G M Gyte; J M Willoughby
Journal:  Clin Exp Immunol       Date:  1977-11       Impact factor: 4.330

4.  Clinical and radiologic improvement of regional enteritis and enterocolitis after treatment with salicylazosulfapyridine.

Authors:  F Goldstein; M G Murdock
Journal:  Am J Dig Dis       Date:  1971-05

5.  Long term therapy of ulcerative colitis with 6-mercaptopurine: a personal series.

Authors:  B I Korelitz; N Wisch
Journal:  Am J Dig Dis       Date:  1972-02

Review 6.  Alterations in immunologic mechanisms in diseases of the gastrointestinal tract.

Authors:  A L Ginsberg
Journal:  Am J Dig Dis       Date:  1971-01

7.  Immunosuppressive drugs. II. Clinical use of immunosuppression.

Authors: 
Journal:  Br Med J       Date:  1970-12-19

8.  Crohn's disease of the appendix.

Authors:  T K Wang; G Tolnai; J S Campbell; J Sirois; E Liepa
Journal:  Can Med Assoc J       Date:  1972-02-05       Impact factor: 8.262

Review 9.  Cost of illness of Crohn's disease.

Authors:  Keith Bodger
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

10.  The long-term risk of continuous immunosuppression using thioguanides in inflammatory bowel disease.

Authors:  Anthony O'Connor; Asghar Qasim; Colm A O'Moráin
Journal:  Ther Adv Chronic Dis       Date:  2010-01       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.